Your search returned 2 results.

Results
	1.	Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial. MedStar authors: Aroda, Vanita R PMID: 28386990 Year: 2017 Citation: Diabetes, Obesity & Metabolism. 19(10):1408-1415, 2017 Oct. Institution: MedStar Health Research Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Aroda VR, Bergenstal RM, Bonadonna RC, Kapitza C, LixiLan-L trial investigators, Niemoeller E, Puig-Domingo M, Souhami E, Stager W, Wysham C, Yu C DOI: https://dx.doi.org/10.1111/dom.12961 Add to cart (remove)
	2.	A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data. MedStar authors: Aroda, Vanita R PMID: 28939018 Year: 2017 Citation: Journal of Diabetes & its Complications. 31(12):1719-1727, 2017 Dec. Institution: MedStar Health Research Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Aroda VR, Gourgari E, Hassanzadeh H, Shoulson I, Wilhelm EE DOI: https://dx.doi.org/10.1016/j.jdiacomp.2017.08.005 Add to cart (remove)

Refine your search